Thermo Fisher Scientific Full Year 2024 Earnings: EPS Beats Expectations

Thermo Fisher Scientific (NYSE:TMO) Full Year 2024 Results

Key Financial Results

• Revenue: US$42.9b (flat on FY 2023).
• Net income: US$6.34b (up 5.7% from FY 2023).
• Profit margin: 15% (in line with FY 2023).
• EPS: US$16.58 (up from US$15.53 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Thermo Fisher Scientific EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%.

The primary driver behind last 12 months revenue was the Laboratory Products and Biopharma Services segment contributing a total revenue of US$23.2b (54% of total revenue). Notably, cost of sales worth US$24.8b amounted to 58% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$7.01b (60% of total expenses). Explore how TMO's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Thermo Fisher Scientific is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.